AbbVie Inc (ABBV)vsTalkspace Inc (TALK)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
TALK
Talkspace Inc
$5.19
0.00%
HEALTHCARE · Cap: $869.39M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 26622% more annual revenue ($61.16B vs $228.87M). ABBV leads profitability with a 6.9% profit margin vs 3.4%. ABBV trades at a lower P/E of 100.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TALK
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+35.5%
Fair Value
$5.86
Current Price
$5.19
$0.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 181.1% YoY
Safe zone — low bankruptcy risk
Revenue surging 29.3% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 6.7% — below average capital efficiency
3.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : TALK
The strongest argument for TALK centers on EPS Growth, Altman Z-Score, Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : TALK
The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. A P/E of 129.8x leaves little room for execution misses. Thin 3.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while TALK is a growth play — different risk/reward profiles.
TALK carries more volatility with a beta of 1.14 — expect wider price swings.
TALK is growing revenue faster at 29.3% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 45/100). TALK offers better value entry with a 35.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Talkspace Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?